Early Cost-Utility Analysis of Ataluren and Eteplirsen in the Treatment of Duchenne Muscular Dystrophy in Egypt.

Objectives: Ataluren and eteplirsen are orphan drugs that delay progression of Duchenne muscular dystrophy in mutation-specific subgroups. They have yet to be approved in Egypt but are expected to reach the market soon. This study describes 2 cost-utility models comparing the drugs with the standard of care.

Estimating Societal Cost of Illness and Patients' Quality of Life of Duchenne Muscular Dystrophy in Egypt.

Objectives: Duchenne muscular dystrophy (DMD) is a rare neuromuscular disease that causes substantial economic burden. This study aims to measure the DMD cost from societal perspective and the quality of life (QOL) of the Egyptian patients.

Methods: We conducted interviews with caregivers of patients with DMD.

Descriptive analysis of medication errors reported to the Egyptian national online reporting system during six months.

Objectives: This study analyzes reports to the Egyptian medication error (ME) reporting system from June to December 2014.

Methods: Fifty hospital pharmacists received training on ME reporting using the national reporting system. All received reports were reviewed and analyzed.